*Refresh the page if the below document does not appear.
GSK Pharma appoints Bhushan Akshikar as new Managing Director
On Monday, the board of directors of Glaxosmithkline pharmaceuticals appointed Bhushan Akshikar as the MD of the company. He will be joining the office from 1st December 2022 and will hold the position for a period of four years.
Hetero Pharma acquires J&Js manufacturing facility in Telangana
Hetero Pharmaceuticals announced that they have acquired the manufacturing unit of Johnson & Johnson at Penjerla in Telangana in a deal worth ₹130 crore, and they are planning to invest about ₹600 crore in the future on its upgradation.
Ajanta Pharma receives "India's Best Managed Companies" award by Deloitte
The specialty pharmaceutical formulation company has been awarded as “Best Managed Companies” in India by Deloitte for 2022. The shortlisting process for the award had strict evaluation of various parameters like management ability for Strategy, Innovation, Governance and Financials along with Culture and Commitment.
Zydus Pharma's two generic drugs receives nod USFDA
The company declared on Monday that they received USFDA’s tentative approval for their two drugs namely Valbenazine capsules and Roflumilast tablets, used for the treatment of tardive dyskinesia. Both the drugs are planned to be manufactured at the formulation manufacturing facility in Ahmadabad.
Roche Pharma establishes second data analytics center in India
Roche Pharmaceuticals have decided to establish an advanced Global Analytics and Technology Center of Excellence (GATE) in Hyderabad which will be the second of its kind in India with a goal to provide innovative data driven solutions.
Takeda Pharma's Dengue Vaccine gets recommendation for approval from EMA
Japanese multinational pharmaceutical company “Takeda Pharma” on Monday reported that the Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) recommended the approval of Takeda’s dengue vaccine candidate named TAK-003.
Covis' drug for preterm birth faces expert panel evaluation
On Monday, USFDA brought half a dozen of its
experts to convince the agency’s Obstetrics,
Reproductive and Urologic Drugs Advisory
Committee to recommend the withdrawal of
the medicine as it failed to prove its
effectiveness. The panel is due to decide the
drug Makena’s fate by Wednesday.
